重组人干扰素治疗疱疹性咽炎123例疗效分析

重组人干扰素治疗疱疹性咽炎123例疗效分析

【摘要】 目的 观察重组人干扰素治疗小儿疱疹性咽炎的临床疗效。方法 将临床确诊疱疹性咽炎的230例患儿随机分为治疗组和对照组。两组常规预防感染及对症治疗，治疗组123例患儿给予重组人干扰素1 μg/(kg•次)，1次/d，肌内注射，连续3 d；对照组107例患儿给予病毒唑10 mg/(kg•d)静脉滴注，1次/d，连续3 d。观察治疗前后患儿的临床症状及体征。结果 治疗组总有效率(98.38%)、热程(3.74±2.3)d，咽部充血及疱疹平均消退时间(4.64±2.3)d，住院期(6.44±2.1)d；对照组总有效率(80.37%)、热程(4.32±2.6)d，咽部充血及疱疹平均消退时间(6.84±2.3)d，住院期(9.3±1.1)d。治疗组在退热时间、疱疹消退时间及住院期方面明显优于对照组(P＜0.05)。结论 重组人干扰素治疗小儿疱疹性咽炎可较快改善病情、缩短病程、提高疗效。

【Abstract】 Objective To explore the clinical efficacy of recombinant human interferon in treatment of pediatric herpes pharyngitis. Methods 230 patients diagnosed with herpes pharyngitis were randomly divided into treatment and control groups. Patients of two groups were treated with conventional prevention of infection and symptomatic treatment. The 123 patients of treatment group were also given recombinant human interferon (1 μg/kg, im. 1 times /d, for 3 days). 107 patiets of control group were treated with ribavirin ［10 mg/(kg•d), iv.1 times/d, for 3 days］.The clinical symptoms and signs, radiological and laboratory data of these patients were retrospectively evaluated. Results In the treatment group, the overall response rate was 98.38%, the median time of thermal process was (3.74± 2.3)d, the median period of throat congestion and herpes was (4.64± 2.3)d, and length of stay (6.44± 2.1)d. In the control group, the total efficiency was 80.37%, the median time of thermal process was (4.32± 2.6)d, throat congestion and the median time of herpes was (6.84± 2.3)d, and length of stay (9.3± 1.1)d. Cooling time, the period of herpes and length of stay of patients in the treatment group was significantly better than that of patients in the control group (P＜0.05). Conclusion Recombinant human interferon in the treatment of pediatic herpes pharyngitis can rapidly improve the condition of patients and efficacy, induce the length of stay.

【Key words】 Herpes pharyngitis；Recombinant human interferon；Efficacy

疱疹性咽炎是由柯萨奇A组病毒感染所致的、小儿急性上呼吸道感染的一种特殊类型，好发于夏秋季［1］；主要治疗为应用抗病毒药物(病毒唑)及对症处理，预防并发症；但既往治疗疗效长、副作用大［2］，使得本组考虑采用重组人干扰素治疗疱疹性咽炎，现将观察结果报告如下。

1 资料与方法

1.1 一般资料 2008年3月至2011年3月间经门诊收治的疱疹性咽炎确诊病例230例，男117例，女113例，年龄2~15岁(平均年龄7.91岁)；并采用随机